All In MedTech

Device Trial Radar · NCT06188585

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

Randomized Controlled Multi-Center Non-Inferiority Trial of UI-EWD (Nexpowder™) vs. Conventional Treatment as First-Line Endoscopic Therapy for Patients With High-Risk Nonvariceal Upper Gastrointestinal Bleeding (TREET)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 278 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

278

Planned (sponsor's estimate)

Start

Jun 21, 2024

Primary completion

Aug 2029

Study completion Sep 2029

Sponsor

Lead sponsor
Medtronic - MITGPublic (MDT)
Sponsor type
Industry
Collaborators
North American Science Associates Ltd.
First posted
Jan 3, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear.

Conditions

  • Acute Gastrointestinal Bleeding

Interventions

  • UI-EWDDevice

    Hemostatic powder administered at index endoscopy

  • Conventional therapyDevice

    Conventional endoscopic therapy (bipolar electrocoagulation or clips or argon plasma coagulation, with or without epinephrine injection) administered at index endoscopy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. No further bleeding during the 7-day period after hemostatic treatmentTime frame: 7 days

Locations

15 sites in 7 countries. Site status is shown where the registry gives one.

  • Yale

    New Haven, Connecticut · Recruiting

  • RUSH University

    Chicago, Illinois · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.